Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Duckers, James M ^a   Shale, Dennis J ^a   Stockley, Robert A ^b   Gale, Nichola S ^a   Evans, Bronwen A J ^c   Cockcroft, John R ^a   Bolton, Charlotte E ^a,d  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; AORTA; ARTERIAL STIFFNESS; ARTICLE; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FORCED EXPIRATORY VOLUME; HEMODYNAMICS; HUMAN; INDEPENDENT VARIABLE; MALE; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; PREDICTOR VARIABLE; PULSE WAVE; SPIROMETRY; AGE DISTRIBUTION; ARTHROPATHY; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SURVIVAL; SURVIVAL RATE; UNITED KINGDOM;

AGE DISTRIBUTION; ALPHA 1-ANTITRYPSIN DEFICIENCY; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; GREAT BRITAIN; HUMANS; JOINT DISEASES; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 78649742484     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-173     Document Type: Article

References (39)

1. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006, 28(6):1245-57. 10.1183/09031936.00133805, 17138679.
2. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33(5):1165-85. 10.1183/09031936.00128008, 19407051.
3. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007, 62(5):411-5. 10.1136/thx.2006.072348, 2117197, 17311843.
4. Blanco I, Bustillo EF, Rodriguez MC. Distribution of alpha1-antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta-analysis. Clin Genet 2001, 60(6):431-41. 10.1034/j.1399-0004.2001.600605.x, 11846735.
5. McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, Newby DE, Murchison JT, Macnee W. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176(12):1208-14. 10.1164/rccm.200707-1080OC, 2176105, 17885263.
6. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, Marumo S, Ogawa E, Hoshino Y, Niimi A, Chin K, Mishima M. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008, 134(6):1244-9. 10.1378/chest.07-3054, 18641115.
7. Forsyth KD, Talbot V, Beckman I. Endothelial serpins-protectors of the vasculature?. Clin Exp Immunol 1994, 95(2):277-82. 10.1111/j.1365-2249.1994.tb06523.x, 1534921, 8306502.
8. Ortiz-Muñoz G, Houard X, Martín-Ventura JL, Ishida BY, Loyau S, Rossignol P, Moreno JA, Kane JP, Chalkley RJ, Burlingame AL, Michel JB, Meilhac O. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009, 23(9):3129-39. 2735359, 19417089.
9. Aldonyte R, Jansson L, Janciauskiene S. Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro. BMC Cell Biol 2004, 5:11. 10.1186/1471-2121-5-11, 400726, 15050036.
10. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, . European Network for Non-invasive Investigation of Large Arteries Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27(21):2588-605. 10.1093/eurheartj/ehl254, 17000623, European Network for Non-invasive Investigation of Large Arteries.
11. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006, 113(5):664-70. 10.1161/CIRCULATIONAHA.105.579342, 16461839.
12. Ahlgren AR, Piitulainen E, Sonesson B, Lanne T. Changes in aortic wall stiffness in men with alpha 1-antitrypsin deficiency. Eur J Vasc Endovasc Surg 1997, 14(4):252-7. 10.1016/S1078-5884(97)80236-5, 9366788.
13. Talmud PJ, Martin S, Steiner G, Flavell DM, Whitehouse DB, Nagl S, Jackson R, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Humphries SE, Syvänne M, . Diabetes Atherosclerosis Intervention Study Investigators Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 2003, 23(4):644-9. 10.1161/01.ATV.0000065196.61663.8D, 12692006, Diabetes Atherosclerosis Intervention Study Investigators.
14. Stakisaitis D, Basys V, Benetis R. Does alpha-1-proteinase inhibitor play a protective role in coronary atherosclerosis?. Med Sci Monit 2001, 7(4):701-11.
15. Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170(12):1286-93. 10.1164/rccm.200406-754OC, 15374843.
16. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(12):1259-65. 10.1164/rccm.200701-067OC, 17363772.
17. American Thoracic Society Committee on the proficiency Standards for Clinical Pulmonary Function Laboratories Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002, 166:111-117. American Thoracic Society Committee on the proficiency Standards for Clinical Pulmonary Function Laboratories.
18. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respiratory Medicine 1991, 85:25-31. 10.1016/S0954-6111(06)80166-6, 1759018.
19. Wilson PW, Paffenbarger RS, Morris JN, Havlik RJ. Assessment methods for physical activity and physical fitness in population studies: report of a NHLBI workshop. Am Heart J 1986, 111(6):1177-92. 10.1016/0002-8703(86)90022-0, 3716991.
20. Bolton CE, Ionescu AA, Evans WD, Pettit RJ, Shale DJ. Altered tissue distribution in adults with cystic fibrosis. Thorax 2003, 58(10):885-9. 10.1136/thorax.58.10.885, 1746496, 14514945.
21. World Health Organisation Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 1984, 84. World Health Organisation.
22. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006, 81(3):353-73. 10.4065/81.3.353, 16529140.
23. Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999, 160(6):1968-75.
24. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132-40. 10.1016/S0140-6736(09)61717-7, 20031199, Emerging Risk Factors Collaboration.
25. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005, 46(1):194-9. 10.1161/01.HYP.0000168055.89955.db, 15911740.
26. Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K, Kohansal R, Burghuber OC. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178(12):1211-8. 10.1164/rccm.200709-1412OC, 18836149.
27. Coulson JM, Rudd JH, Duckers JM, Rees JI, Shale DJ, Bolton CE, Cockcroft JR. Excessive Aortic Inflammation in Chronic Obstructive Pulmonary Disease: An 18F-FDG PET Pilot Study. J Nucl Med 2010, 51(9):1357-60. 10.2967/jnumed.110.075903, 20720052.
28. Chignard M, Hazouard E, Renesto P, Laine A, Guidet B, Offenstadt G. Plasma antiproteinase screen and neutrophil-mediated platelet activation. A major role played by alpha 1 antitrypsin. Biochim Biophys Acta 1994, 1224(3):433-40. 10.1016/0167-4889(94)90279-8, 7803500.
29. Aldonyte R, Hutchinson TE, Jin B, Brantly M, Block E, Patel J, Zhang J. Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro. COPD 2008, 5(3):153-62. 10.1080/15412550802092936, 18568839.
30. Janciauskiene S, Dominaitiene R, Sternby NH, Piitulainen E, Eriksson S. Detection of circulating and endothelial cell polymers of Z and wild type alpha 1-antitrypsin by a monoclonal antibody. J Biol Chem 2002, 277(29):26540-6. 10.1074/jbc.M203832200, 12023970.
31. Aldonyte R, Jansson L, Ljungberg O, Larsson S, Janciauskiene S. Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerization. Histopathology 2004, 45(6):587-92. 10.1111/j.1365-2559.2004.02021.x, 15569049.
32. Dahl M, Tybjaerg-Hansen A, Sillesen H, Jensen G, Steffensen R, Nordestgaard BG. Blood pressure, risk of ischemic cerebrovascular and ischemic heart disease, and longevity in alpha(1)-antitrypsin deficiency: the Copenhagen City Heart Study. Circulation 2003, 107(5):747-52. 10.1161/01.CIR.0000049642.20484.5D, 12578879.
33. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, . CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators CAFE Steering Committee and Writing Committee Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113(9):1213-25. 10.1161/CIRCULATIONAHA.105.595496, 16476843, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators CAFE Steering Committee and Writing Committee.
34. McEniery CM, McDonnell B, Munnery M, Wallace SM, Rowe CV, Cockcroft JR, Wilkinson IB, . Anglo-Cardiff Collaborative Trial Investigators Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension 2008, 51(6):1476-82. 10.1161/HYPERTENSIONAHA.107.105445, 18426997, Anglo-Cardiff Collaborative Trial Investigators.
35. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166(3):333-9. 10.1164/rccm.2110093, 12153966.
36. Maciewicz RA, Warburton D, Rennard SI. Can increased understanding of the role of lung development and aging drive new advances in chronic obstructive pulmonary disease?. Proc Am Thorac Soc 2009, 6(7):614-7. 10.1513/pats.200908-094RM, 19934358.
37. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009, 135(1):173-80. 10.1378/chest.08-1419, 19136405.
38. Vivodtzev I, Minet C, Wuyam B, Borel JC, Vottero G, Monneret D, Baguet JP, Lévy P, Pépin JL. Significant improvement in arterial stiffness after endurance training in COPD patients. Chest 2010, 137(3):585-92. 10.1378/chest.09-1437, 19880908.
39. Duckers JM, Bolton CE, Evans BA, Evans W, Stone MD, Shale DJ. Osteoporosis and loss of bone mineral density in corticosteroid-naïve male patients with chronic obstructive pulmonary disease [abstract]. Thorax 2008, 63(suppl vii):A23. S48.